Latest news with #Reddy'sLaboratories
Hans India
6 days ago
- Business
- Hans India
Mahindra University commends 956 Graduates at Fourth Convocation
Hyderabad: Mahindra University recently held its fourth annual convocation, celebrating the achievements of 956 students at its Bahadurpally campus. The graduating class included 943 students from its engineering, management, law, and education schools, as well as 13 PhD scholars. The ceremony was attended by proud parents, faculty, and special guests. The event's Chief Guest was G V Prasad, Co-Chairman and Managing Director of Dr Reddy's Laboratories. The ceremony was presided over by Mahindra University Chancellor, Anand Mahindra, and attended by other dignitaries including Mohit Joshi, a Member of the Board of Management, Mahindra University, and CEO & MD, Tech Mahindra, and the university's Vice Chancellor, Dr YajuluMedury. In his address, Prasad encouraged the graduates to be collaborative, highlighting the need to build communities and workplaces that foster innovation. He urged them to embrace lifelong learning and believe in their ability to overcome self-limiting beliefs. Anand Mahindra's speech emphasised the university's mission to educate 'citizens for and of a better world'. He called on the graduates to act as both inheritors and architects of the future, living by their values and shaping a world rooted in sustainability, inclusivity, and justice. This convocation was a particularly significant milestone as it marked the first graduating class for several new programmes, including the Master of Business Administration (MBA), Bachelor of Laws (LLB), Master of Arts (MA), and Bachelor of Technology (B. Tech) Nanotechnology. Mohit Joshi spoke about the importance of professionals who can bridge disciplines and innovate with purpose. He also noted the growing partnership between the university and industry, with Tech Mahindra playing a key role in this ecosystem. Earlier in the day, G V Prasad and Anand Mahindra inaugurated new biotechnology labs, while Mahindra had opened the Centre for Risk Management on Saturday. These new initiatives underscore the university's dedication to research and innovation.
The Hindu
7 days ago
- Science
- The Hindu
943 degrees, 13 PhDs, 21 gold medals given at Mahindra University convocation
Build a mosaic of experiences, collaborate like flocking birds which learn together and thrive, and believe in the ability to overcome self-limiting beliefs, Co-Chairman and Managing Director of Dr Reddy's Laboratories G.V. Prasad told graduating students at Mahindra University here on Sunday. While learning for growth and making an impact, he encouraged the students to build communities and work places that break barriers and promote innovation. The fourth convocation of Mahindra University saw degrees awarded to 943 students from engineering, management, law, and education disciplines, and 13 Besides, 21 students were awarded gold medals for meritorious academic performance. It was the first convocation for students of MBA, LLB, MA, and B. Tech nanotechnology programmes. University Chancellor Anand Mahindra called upon students to not only embody the values of compassion, critical thinking, and ethics, but also take ownership as architects of a brighter future. He urged them to live by their values and shape a world rooted in sustainability, inclusivity, and justice. CEO and MD of Tech Mahindra, and Board Member Mohit Joshi stressed on the need for professionals who can bridge disciplines, question the status quo, and innovate with purpose. He said the university will thrive on partnerships across industries. Mr. Prasad, Mr. Mahindra, Mr. Joshi, and Vice-Chancellor Yajulu Medury inaugurated the new biotechnology labs. On Saturday, Mr. Mahindra inaugurated the centre for risk management.
News18
27-07-2025
- Health
- News18
Sun Pharma, Lupin, Dr Reddys recall products in US market
New Delhi, Jul 27 (PTI) Domestic drug majors Sun Pharma, Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to 'Failed Dissolution Specifications", the US health regulator stated. The medication is used to treat attention deficit hyperactivity disorder (ADHD). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to 'Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories, Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. PTI MSS HVA view comments First Published: July 27, 2025, 10:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
23-07-2025
- Business
- Time of India
Dr Reddy's PAT rises 2% despite record quarterly revenues in Q1FY26
1 2 Hyderabad: Despite clocking its highest-ever quarterly revenues during the first quarter ended June 30, pharma major Dr Reddy's Laboratories (DRL) on Wednesday said it posted only a marginal 2% rise in profit after tax for Q1 of FY26 at Rs 1,418 crore, as against Rs 1,392 crore in the same period of FY25. The company posted an 11% rise in revenues at Rs 8,545 crore during Q1FY26, compared to Rs 7,673 crore during Q1FY25. Dr Reddy's said revenues from global generics grew 10% during Q1FY26 at Rs 7,562 crore, compared to Rs 6,886 crore in Q1FY25, despite an 11% drop in generics revenues from North America to Rs 3,412 crore from Rs 3,846 crore, due to higher price erosion led by Lenalidomide, the generic version of the blockbuster multiple myeloma drug Revlimid. Revenues from the European generics market showed the steepest growth at 142% during the quarter at Rs 1,274 crore from nearly Rs 527 crore, even as revenues from the Indian market showed an 11% rise to Rs 1,471 crore from Rs 1,325 crore, and those of emerging markets increased 18% from Rs 1,188 crore. US markets accounted for 40% of the revenues during the quarter, while India contributed 17%, emerging markets 16%, and Europe 15%. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad
Time of India
23-07-2025
- Business
- Time of India
Dr Reddy's plans to launch generic of Novo's weight-loss drug next year, CEO says
(You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Drugmaker Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk 's blockbuster weight-loss drug Wegovy in 87 countries next year, CEO Erez Israeli said in a press briefing on launch plans for the generic version of semaglutide, which is the active ingredient of Novo's Wegovy and Ozempic , comes at a time when drugmakers are racing to grab a share of the global obesity drugs market that is expected to be valued at $150 billion by early 2030s.
